A temperature-sensitive, self-adhesive hydrogel to deliver iPSC-derived cardiomyocytes for heart repair

Induced pluripotent stem cells (iPSCs) from patients’ somatic tissues provide a viable source to create autologous cardiomyocytes (CMs) for potential cardiac-related cell therapies. However, a gap between the generation of iPSC-derived cardiomyocytes (iPSC-CMs) and the successful intra-cardiac engraftment of the cells to restore heart function remains to be bridged. Clinical data reporting engraftment of cells within human heart tissue has not been without its challenges, with significant cell loss from the site of delivery due to the physical stress of the cardiac cycle and the hostile inflammatory response within the infarct zone.[1–3] Hydrogels have been proven to support the survival of multiple cell types and have served as a platform for cell transplantation.[4, 5] Yet the use of tissue-adhesive, temperature-sensitive hydrogels to deliver iPSC-derived cardiomyocytes to infarcted heart remains to be explored. Therefore, we developed a polymer hydrogel to encapsulate, deliver, and integrate iPSC-CMs into infarcted myocardium to restore heart function. A temperature-sensitive biodegradable copolymer (polyethylene glycol-co-poly-e-caprolactone (PEG-PCL)) was synthesized [6] and conjugated with a collagen-binding peptide (SYIRIADTNIT). [7] The polymer was soluble in aqueous solutions at room temperature and underwent solution-to-gel transition at 37°C (Fig. 1 a,b).[6] As the peptide-modified polymer had a strong affinity to collagen I in vitro (Fig. 1c), it was expected that it would significantly increase the binding of the hydrogel to an infarcted heart, thus immobilizing iPSC-CMs within the damaged myocardium. Functional, beating cardiomyocytes were derived from patient fibroblast-derived iPSCs using a “Matrigel sandwich” method.[8] Cardiac differentiation was confirmed by fluorescence-activated cell sorting (FACS) and by immunostaining with known cardiac markers cardiac troponin T (cTNT), ryanodine receptor 2 (RYR) and α-actinin (Fig. 1f). The iPSC-CMs encapsulated in the polymer hydrogel at 37°C for two weeks maintained their viability (Fig. 1g) and cardiac phenotype, as evidenced by strong expression of troponin T and Nkx2.5 (Fig. 1h); thus, PEG-PCL does not appear to have obvious toxic effects on iPSC-CMs. Fig. 1 PEG-PCL copolymer was (a) dissolved in PBS at RT and (b) gelled at 37°C within 5 min (Sol-gel transition). Collagen-binding study was performed by adding peptide-modified polymer to collagen-coated surface at 37°C, and unbound polymer ... Engraftment of iPSC-CMs into infarcted myocardium using the peptide-modified hydrogel and its impact on infarcted heart function and structure were assessed with a rat myocardial infarction (MI) model. All animal surgery and animal care were approved by the Institutional Animal Care and Use Committee (IACUC) at Vanderbilt University (protocol: M/12/074). The left anterior descending (LAD) coronary artery of nude rats was ligated to induce MI. At 30 minutes post-MI, iPSC-CMs alone, or modified copolymer solution with or without iPSC-CMs (2–4 million/rat) were injected around the infarct border zone. A negative control group received the LAD ligation and phosphate-buffered saline (PBS) injection without cells or copolymer. At two weeks post-injection, heart dimensions and functional output were assessed by echocardiography. All groups had ventricular dilation and reduced fractional shortening (FS) (Fig. 2). However, rats treated with iPSC-CM-encapsulated copolymer demonstrated significantly less decline in FS (Δ= −6.37±0.49%) compared to other groups (Δ= −12.77±2.04%, −11.44±2.04% and −12.65±1.53% for PBS control, iPSC-CM only, and polymer only groups, respectively (Fig. 2a). p=0.016 vs. PBS, p=0.021 vs. iPSC-CM only, and p=0.005 vs. polymer only). Overall, the iPSC-CM plus polymer group demonstrated 50.1%, 28.2% and 49.6% improvement in LV systolic function over PBS, iPSC-CM only and polymer only groups (Fig. 2b). Moreover, rats treated with iPSC-CM plus polymer demonstrated a trend toward less LV enlargement (Δ= 15.07±3.24%) compared to other groups (Δ=24.44±3.99%, 25.02±2.03% and 23.17±4.51% for PBS control, iPSC-CM only, and polymer only groups, respectively; Fig. 2c) although this reached statistical significance only in comparison to the iPSC-CM group (p=0.032). Overall, iPSC-CM plus polymer group demonstrated 38.3%, 39.8% and 35.0% less LV enlargement over PBS, iPSC-CM only and polymer only groups, suggesting that iPSC-CM encapsulated in polymer curtailed adverse ventricular remodeling better than other treatment modalities. Fig. 2 The effects of hydrogel-encapsulated iPSC-CMs on left ventricle function and remodeling. (a–c) Echocardiography was performed before the ligation of rat LAD coronary arteries (baseline) and again 2 weeks post-delivery (n=5 rats per group). (a, ... Histological examination of the hearts was performed, and the LV anterior free wall thickness was measured using ImageJ and averaged from 3 randomly selected regions in each rat heart. Result demonstrated that, in addition to LV chamber enlargement, the LAD ligation resulted in dramatic thinning and significant fibrosis of the LV anterior free wall at two weeks in control groups (Fig. 2e). In contrast, heart injected with polymer-encapsulated iPSC-CMs had smaller LV chamber, thicker LV free wall and less fibrosis (Fig. 2e). Overall, hearts in the iPSC-CM plus polymer group were significantly thicker than all other groups; the average LV anterior wall thickness of cell plus polymer group was 2.46±0.06mm, compared with 0.48±0.07, 0.35±0.05 and 0.39±0.02mm in PBS, cell only and polymer only groups, respectively (Fig. 2d, p<0.001). In summary, implantation of iPSC-CMs encapsulated in polymer hydrogel was much more effective at limiting adverse LV remodeling and preserving cardiac function after MI than other treatment modalities. Importantly, as implantation of iPSC-CMs or polymer alone did not elicit as favorable outcomes as the iPSC-CMs plus polymer group, we attribute the latter group’s synergistic effects to enhanced survival of transplanted iPSC-CMs in vivo. Consistent with this notion, staining for human nuclei confirmed the presence of iPSC-CMs, delivered with the polymer hydrogel, in the peri-infarct region of the host rat myocardium at 2 weeks (Fig. 2f); moreover, the implanted cells maintained their cardiac phenotype, as demonstrated by positive staining of cardiac α-actinin (Fig. 2f). By contrast, no human nuclei were detected in hearts of control groups at 2 weeks. In conclusion, we describe a temperature-sensitive, collagen-binding hydrogel based system to deliver human iPSC-derived cardiomyocytes to improve cardiac structure and function in infarcted rat heart. Moreover, our studies indicate that the beneficial effects of encapsulating iPSC-CMs in hydrogel are mediated through enhanced survival of transplanted iPSC-CMs in vivo. While future studies are needed to demonstrate long-term functional engraftment of transplanted cells, our study illustrates a promising biomaterial-based approach to overcome a commonly recognized obstacle to the potentially revolutionary cell-based approaches to repair failing hearts: survival of donor cells in the infarcted heart.